Menu

Report Library

All Reports

Biomedtracker Q3 2017 Outlook Report

July 05, 2017

In this report, we cover catalysts from 21 drugs expected to occur in Q3 2017. For each drug, the likelihood of Phase/PDUFA review success and overall Likelihood of Approval (LOA) given their particular phase, drug class, and disease group are provided. The results of the catalysts highlighted in our Q2 2017 Outlook Report can be found on Page 4. At the end of this report, we have included a list of Large Impact catalysts through Q3 2017.

For the full report, please download the PDF version at the top of this page. Additionally, the catalyst list is provided in Excel by downloading the supplemental material at the top of this page.


Meddevicetracker Q3 2017 Outlook Report

Separately, Biomedtracker’s sister product, Meddevicetracker has published a concurrent report on 11 device catalysts expected to occur in Q2 2017. This report can be downloaded for free here.

For more information on Meddevicetracker, visit its website www.meddevicetracker.com.


Like our report? Have any questions or feedback? Please let us know at askanalyst@sagientresearch.com.

For our disclosures, please read the Biomedtracker Research Standards.
Indications Covered: Acute Lymphoblastic Leukemia (ALL)
Acute Myelogenous Leukemia (AML)
Alzheimer's Disease (AD)
Breast Cancer
Dry Age-Related Macular Degeneration (Dry AMD)/Geographic Atrophy (Ophthalmology)
Duchenne Muscular Dystrophy (DMD)
Epidermolysis Bullosa
Fragile X Syndrome
Glaucoma / Ocular Hypertension (Ophthalmology)
Hereditary Transthyretin (hATTR) Amyloidosis With Polyneuropathy (Familial Amyloid Polyneuropathy)
Levodopa-Induced Dyskinesia
Nasal Polyposis
Non-Small Cell Lung Cancer (NSCLC)
Rheumatoid Arthritis (RA)
Seizure Disorders (Epilepsy)
Sickle Cell Disease
Skin and Skin-Structure Infections (Antibacterial)
Tardive Dyskinesia
Urinary Tract and Reproductive Tract Infections (Antibacterial)

 Additional Resources: